These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22366662)

  • 1. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.
    van Nooten F; Holmstrom S; Green J; Wiklund I; Odeyemi IA; Wilcox TK
    Drug Discov Today; 2012 Jun; 17(11-12):615-22. PubMed ID: 22366662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
    Ijzerman MJ; Steuten LM
    Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A primer on the assessment of medical technologies.
    Matuszewski KA
    Pharm Pract Manag Q; 1997 Jan; 16(4):53-65. PubMed ID: 10164160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of health outcomes.
    Thavorncharoensap M
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S27-32. PubMed ID: 24964696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 3: payment.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Nov; 3(11):842-50. PubMed ID: 17412183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of cost effectiveness in technology evaluation.
    Valk PE
    Q J Nucl Med; 2000 Jun; 44(2):197-203. PubMed ID: 10967629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breaking up is hard to do: why disinvestment in medical technology is harder than investment.
    Haas M; Hall J; Viney R; Gallego G
    Aust Health Rev; 2012 May; 36(2):148-52. PubMed ID: 22624634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):105-11. PubMed ID: 10967621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining quality health care with outcomes assessment while achieving economic value.
    Shaw LJ; Miller DD
    Top Health Inf Manage; 2000 Feb; 20(3):44-54. PubMed ID: 10747434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical context of technology assessment.
    Smits HL
    J Health Polit Policy Law; 1984; 9(l):31-40. PubMed ID: 11650667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can CER be an effective tool for change in the development and assessment of new drugs and technologies?
    Brixner DI; Watkins JB
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S06-11. PubMed ID: 22663293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment: research trends and future priorities in Europe.
    Nielsen CP; Funch TM; Kristensen FB
    J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions.
    Fugel HJ; Nuijten M; Faulkner E
    J Med Econ; 2014 May; 17(5):305-11. PubMed ID: 24654841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economics of market access for biopharmaceuticals and biosimilars.
    Simoens S
    J Med Econ; 2009 Sep; 12(3):211-8. PubMed ID: 19723019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.